Status:

COMPLETED

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Lead Sponsor:

Janssen R&D Ireland

Conditions:

Chronic Hepatitis C

Genotype 4 Chronic Hepatitis C

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to show superiority of simeprevir (SMV) in combination with sofosbuvir for 12 weeks versus a historical control. Historical control will be a composite of the observed his...

Detailed Description

This is a Phase 3, open-label (all people know the identity of the intervention), single-arm, multicenter study (conducted at multiple sites). The study consists of 3 periods: a Screening period (up t...

Eligibility Criteria

Inclusion

  • Subjects with confirmed hepatitis C virus (HCV) with HCV RNA greater than (\>) 10000 international unit per milliliter (IU/mL)
  • Subjects who are treatment naive or treatment-experienced.
  • Subjects must have documentation of a liver biopsy or fibroscan or agree to have one during screening
  • Subjects with cirrhosis must have an hepatic imaging procedure (ultrasound, CT scan or magnetic resonance imaging \[MRI\]) within 6 months before the screening visit (or during the screening period) with no findings suspicious for hepatocellular carcinoma (HCC)
  • Women of childbearing potential or men with a female partner of childbearing potential must agree to use an effective form of contraception, or not be heterosexually active, or of nonchildbearing potential

Exclusion

  • Evidence of clinical hepatic decompensation
  • Any liver disease of non-HCV etiology
  • Subjects with a past history of treatment with an approved or investigational DAA
  • Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)
  • Infection/co-infection with HCV non-genotype 4

Key Trial Info

Start Date :

January 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT02250807

Start Date

January 1 2015

End Date

December 1 2015

Last Update

November 17 2016

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Badalona, Spain

2

Barcelona, Spain

3

Madrid, Spain

4

Santander, Spain